Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.
Coherus Biosciences develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Gyala Therapeutics is focused on developing new CAR-T therapies for treating hematological malignancies.
Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
Positrigo is a company dedicated to the development, production, and sales of dedicated brain positron emission tomography (PET) scanners.
Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.
Neocis develops robot-assisted dental implant surgery with the aim of transforming dental surgery using advanced robotics.
EsoBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.
EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.
Neumirna Therapeutics is a pharmaceutical company that develops therapeutics for the treatment of neurological diseases.
Immune-Onc Therapeutics is a newly established biopharmaceutical company that develops therapeutic antibodies for cancer treatment.
Terns Pharmaceuticals develops small-molecule therapies for chronic diseases including cancer, metabolic disorders, and liver conditions.
Sanegene Bio develops an RNAi drug discovery platform designed for unmet clinical needs.
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.
CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.
Tebra provide independent healthcare practices with digital tools and support to thrive in a new era of healthcare.
Pulmobiotics is a pre-clinical life sciences company.
BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.
Platelet Biogenesis is an allogeneic cell therapy company that focuses on platelet biology.
Caidya is a clinical research organization that provides personalized solutions for various therapeutic areas.
Vivo Capital has invested in 165 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Vivo Capital's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 20 different industry categories.
Among tracked funding rounds, Terns Pharmaceuticals received $650.0M in a Post-IPO Equity round. Vivo Capital's total known invested capital is $12.4B.
Vivo Capital's average investment size is $110.3M across its portfolio of 165 companies.
Recent Vivo Capital portfolio additions include ADARx Pharmaceuticals, Coherus Biosciences, Aligos Therapeutics, Gyala Therapeutics, Integra Therapeutics. These companies were founded in 2020 or later.